Shilpa Medicare Limited

Shivakumar Pradeep

Sreenivasa Reddy

Agadihiremath Thippeswamy

Rajendar Medishetty

Ravi Vamsi Peri

Krishnamurthy Toppaladoddi

Kiran K Jadhav

Nijaguni Revansiddayya Rudraswamy Math

Prashanth S

Rizwan Ahmed

Nagaraju Dasari

Narayanaswamy Abhilash

Andanayya Saraganachari

Abhilash Narayanaswamy

Saraganachari Andanayya

Guptha Chinni Guru Deva

Sreenivas Reddy

The present invention relates to a dispersible tablet comprising at least 70% w/w of abiraterone acetate based on the total weight of the tablet and at least one pharmaceutically excipient selected from group consisting of diluents, binders, surfactants, glidants, disintegrants, lubricants, sweeteners and flavorants and further relates to the process for the preparation thereof.

Dispersible tablets of abiraterone acetate

The present invention relates to a pharmaceutical liposomal composition comprising of about 0.8% w/w to about 1% w/w of docetaxel, about 30% w/w to about 38% w/w of Soya Phosphatidyl Choline, about 0.2% w/w to about 0.8% w/w of Sodium Cholesteryl Sulfate, about 61% w/w to about 68% w/w of Sucrose and a pH adjusting agent, wherein the pH of liposomal composition is less than 3.5 and the process for preparation thereof.

Composition of docetaxel liposomal injection with high drug loading

The present invention relates to a composition for topical application for preventing hair loss, androgenic alopecia (AA) and stimulating hair growth having dutasteride. The composition for topical application for preventing hair loss and stimulating hair growth according to the present invention provides equal or superior hair loss prevention and hair growth stimulating effects while using much smaller dosage than the conventional compositions (oral dosage form) which use finasteride and dutasteride.

Topical compositions of dutasteride

The present invention relates to an aqueous ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma, the solution comprising at least 0.5 w/v % brinzolamide dissolved in the solution; hydroxy-propyl-&#x3b2;-cyclodextrin; polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer; and water and/or the process for preparation thereof.

Ophthalmic compositions of brinzolamide

The present invention provides a stable, ophthalmic aqueous composition for topical administration comprising acetazolamide and an aqueous liquid capable of forming a pharmaceutically acceptable gel in situ when applied topically to a patient, said composition has the pH of less than 4.5.

Acetazolamide ophthalmic solution

The present invention relates to a stable, non-aqueous liquid, formulation consisting essentially of melphalan, or a pharmaceutical acceptable salt thereof; and one or more solvents selected from group consisting of dimethyl acetamide, polyethylene glycol, ethanol, propylene glycol, dimethyl sulfoxide, N-methylpyrrolidone and glycerol; wherein said formulation is free of antioxidants, organic acid and added chloride ions; and the process for preparation thereof.

Stable melphalan liquid injectable formulations

The present invention relates to a pharmaceutical composition comprising lenvatinib mesylate and a stabilizer in an amount of about 10% to about 20% based on the total weight of the composition, wherein the stabilizer is selected from the group consisting of calcium hydroxide and potassium hydroxide; and its process for preparation thereof.

Growing community of inventors

Vizianagaram, India

Shivakumar Pradeep